Asset profile

trenibotulinumtoxinE · AbbVie (ABBV)

Indication: moderate to severe glabellar lines
Also known as: Boey, Boey®, TrenibotE

Company

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products…

Start live analysis of ABBV Run 8-agent AI analysis Stock overview

On the calendar

Nothing scheduled in this window.

Timeline

Newest first.

Decision-grade

Jul 17, 2026

12:00 PM

AbbVie receives EU approval for Boey (trenibotulinumtoxinE) glabellar lines

FDA approvalCompany press release Open record

Material

May 21, 2026

08:10 PM

AbbVie: CHMP positive opinion for Boey (trenibotulinumtoxinE) glabellar lines

EMA opinionCompany press release Open record

Decision-grade

Apr 23, 2026

08:05 PM

AbbVie receives FDA CRL for TrenibotE BLA over manufacturing

Complete response letterCompany press release Open record

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Sep 15, 2026

Primary endpoint metUnknown

Overall survival significant or trendingUnknown

US / Western patient shareUnknown

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentConcern

AbbVie receives FDA CRL for TrenibotE BLA over manufacturing

Related companies

Each relationship is backed by the filing that stated it.

ABBVAbbVieOwner

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

More from AbbVie

Other drugs and candidates from the same company tracked in this sector.

atogepantmenstrual migraine DecnupazAdult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)epcoritamabrelapsed/refractory diffuse large B-cell lymphoma etentamigtriple-class exposed relapsed/refractory multiple myeloma glecaprevir/pibrentasviracute hepatitis C virus infection linaclotidefunctional constipation (FC) in pediatric patients 2 years of age and older risankizumabmoderate to severe plaque psoriasis in children and adolescents six years of age and older SKINVIVE by JUVÉDERMreduction of horizontal neck lines for improvement of neck appearance in adults over 21 upadacitinibsevere alopecia areata venetoclaxpreviously untreated chronic lymphocytic leukemia